Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.78 |
| ▸ | DRD1 | P21728 | 4/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.78 |
| ▸ | HTR2A | P28223 | 3/20 | 0.78 |
| ▸ | HRH1 | P35367 | 3/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.78 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.76 |
| ▸ | LMNA | P02545 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tripelennamine SCHEMBL29600775 | 0.88 | CHRM2 (1.00) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Tripelennamine SCHEMBL17970 | 0.88 | CHRM2 (1.00) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| SCHEMBL16491454 | 0.87 | CHRM2 (0.81) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Tripelennamine SCHEMBL98916 | 0.87 | KDM4E (1.00) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Tripelennamine SCHEMBL1652325 | 0.87 | CHRM2 (0.97) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Tripelennamine SCHEMBL29363256 | 0.87 | KDM4E (1.00) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| SCHEMBL8386885 | 0.86 | CHRM2 (0.78) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Chloropyramine SCHEMBL30021 | 0.86 | CYP2D6 (1.00) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| SCHEMBL30280471 | 0.86 | CHRM2 (0.78) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Chloropyramine SCHEMBL30566745 | 0.86 | CYP2D6 (1.00) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394253-B2 | Kinase protein binding inhibitors | HEALTH RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394253-B2 | Kinase protein binding inhibitors | HEALTH RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150051245-A1 | KINASE PROTEIN BINDING INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| US-20150051245-A1 | KINASE PROTEIN BINDING INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| WO-2013074517-A1 | KINASE PROTEIN BINDING INHIBITORS | ROSWELL PARK CANCER INSTITUTE (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051245-A1 | KINASE PROTEIN BINDING INHIBITORS | PACSIN2, PRKCH, CKS1B | CHRM2 4876/4885ADRA2A 4313/4885DRD1 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.